US FDA), and other western regulators for emergency use. The vaccine is also authorised for use in teens in the US. It has an efficacy of over 90% in preventing the infection.
Meanwhile, on Tuesday, the Drugs Controller General of India (DCGI) granted approval to Cipla Ltd to import the COVID-19 vaccine developed by Moderna Inc for restricted emergency use.
Moderna's shot will be the fourth vaccine in India after AstraZeneca's Covishield, Bharat Biotech's Covaxin and Sputnik V developed by Russia's Gamaleya Institute.
Moderna on June 27 informed DCGI that the US government has agreed to donate a certain number of doses of its COVID-19 vaccine through COVAX to India for use here and sought an approval from the Central Drugs Standard